GeneHealth - Your precision medicine

X-linked Intellectual Disability-short Stature-overweight Syndrome

Disease Details

Family Health Simplified

Buy Membership

Description: X-linked intellectual disability-short stature-overweight syndrome is a genetic disorder characterized by intellectual disability, shorter-than-average height, and an increased tendency to be overweight.
Type: X-linked intellectual disability-short stature-overweight syndrome is transmitted via an X-linked pattern of inheritance.
Signs And Symptoms: X-linked intellectual disability-short stature-overweight syndrome is a rare genetic disorder. The signs and symptoms typically include:

1. **Intellectual Disability:** Varying degrees of cognitive impairment, often identified in early childhood.
2. **Short Stature:** Below-average height for age and gender, noticeable during childhood.
3. **Overweight:** Increased body weight, often becoming evident in childhood or adolescence.
4. **Dysmorphic Features:** Abnormal facial and other physical features may be present, but can vary widely among affected individuals.

Additional symptoms may include developmental delays, behavioral issues, and other congenital anomalies, depending on the specific genetic mutation and its effects.
Prognosis: X-linked intellectual disability-short stature-overweight syndrome, also known as Klinefelter syndrome, is a genetic condition characterized by intellectual disability, short stature, and overweight. The prognosis varies depending on the severity of symptoms and the implementation of early interventions and supportive care. Individuals may experience varying levels of intellectual disability and physical manifestations, but with appropriate medical, educational, and social support, many can lead fulfilling lives. Life expectancy is generally normal, although comorbid conditions may need to be managed.
Onset: X-linked intellectual disability-short stature-overweight syndrome typically has an onset in early childhood.
Prevalence: The prevalence of X-linked intellectual disability-short stature-overweight syndrome is not clearly established due to its rarity. Detailed epidemiological data may not be available for this specific syndrome.
Epidemiology: **Epidemiology:**
X-linked intellectual disability-short stature-overweight syndrome (XLIDSSO) is a rare genetic disorder. Its exact prevalence is not well-established due to the rarity and the potential underdiagnosis of the condition. The syndrome predominantly affects males, as it is linked to mutations on the X chromosome. Females can be carriers and may exhibit milder symptoms or no symptoms at all.

**Nan:**
The term "nan" is unclear in this context—if it refers to "not a number" or another specific term, please provide additional context for a precise answer.
Intractability: X-linked intellectual disability with short stature and overweight syndrome is currently considered intractable, as there are no available cures. Management typically involves supportive care and symptomatic treatment to improve the quality of life. Genetic counseling is also recommended for affected families.
Disease Severity: The disease severity for X-linked intellectual disability-short stature-overweight syndrome can vary significantly among affected individuals. Symptoms can range from mild to severe, depending on the specific genetic mutation and its impact on the individual. Common features of the syndrome include intellectual disability, reduced growth leading to short stature, and an increased tendency to be overweight. The overall impact on quality of life and daily functioning can differ from person to person.
Healthcare Professionals: Disease Ontology ID - DOID:0112056
Pathophysiology: X-linked intellectual disability-short stature-overweight syndrome is a genetic disorder caused by mutations in genes located on the X chromosome. The pathophysiology typically involves disruptions in normal gene function that affect brain development, growth regulation, and metabolism. These mutations may impair the production or function of proteins necessary for neuronal development and signaling, hormone regulation, or metabolic processes, leading to intellectual disability, reduced growth, and a propensity for overweight or obesity. The exact mechanisms can vary depending on which specific genes are involved.
Carrier Status: The term "carrier status" typically refers to whether a person carries one copy of a mutated gene associated with a recessive disorder, meaning they do not exhibit symptoms but can pass the mutation to their offspring. For X-linked intellectual disability-short stature-overweight syndrome (XL-IDSS), the carrier status predominantly affects females due to the X-linked inheritance pattern. Since males have only one X chromosome, the presence of the mutated gene typically results in the disorder, while females with one mutated and one normal X chromosome are generally carriers and might show mild or no symptoms depending on the specifics of X-inactivation.

Since your inquiry included "nan" without further context, it's assumed to be irrelevant or an error in the context of this question. If you intended to include specific information or data, please provide more context.
Mechanism: X-linked intellectual disability-short stature-overweight (XLS) syndrome is associated with mutations in a specific gene on the X chromosome. The most commonly implicated gene in this syndrome is **MED12**.

**Mechanism**: XLS syndrome arises due to mutations in the MED12 gene, which is crucial for normal cognitive development, growth regulation, and metabolism.

**Molecular mechanisms**:
1. **Gene Mutation**: Mutations in MED12 disrupt the gene's function. MED12 encodes a subunit of the Mediator complex, which is a pivotal component in the regulation of gene transcription.
2. **Transcriptional Dysregulation**: MED12 is involved in the regulation of RNA polymerase II-mediated transcription, which is essential for the expression of a wide variety of genes. Mutations in MED12 can impair the transcriptional regulation process, leading to abnormal expression of genes that are critical for brain function, growth, and metabolic processes.
3. **Impact on Development**: Disrupted transcriptional control due to MED12 mutations can lead to deficits in neural development and function, resulting in intellectual disabilities. Additionally, these disruptions can affect growth regulation pathways, leading to short stature and overweight.

Overall, the molecular pathogenesis of XLS syndrome is complex and involves intricate gene-regulatory networks that are disrupted due to mutations in MED12, leading to the phenotypic characteristics of the syndrome.
Treatment: There is no specific cure for X-linked intellectual disability-short stature-overweight syndrome (also known as MRXSSO). Treatment typically focuses on managing the symptoms and may include:

1. **Educational Support:** Special education programs tailored to the individual's specific learning needs.
2. **Behavioral Therapy:** To address behavioral issues and improve adaptive functioning.
3. **Nutritional Counseling:** To manage obesity and promote a healthy lifestyle.
4. **Medical Monitoring:** Routine check-ups to monitor growth, development, and manage any associated medical conditions.
5. **Support Services:** Involvement of physical therapists, occupational therapists, speech and language therapists as needed.

It's important for treatment plans to be individualized based on the specific needs and symptoms of the person affected by the syndrome.
Compassionate Use Treatment: X-linked intellectual disability-short stature-overweight syndrome (also known as Snyder-Robinson syndrome) is a rare genetic disorder. It is caused by mutations in the SMS gene.

Since it is a rare condition, there are no established treatments specifically approved for this syndrome. However, some approaches may be considered:

1. **Compassionate Use Treatment**: Physicians may consider compassionate use of treatments that are not yet approved for Snyder-Robinson syndrome but are available for other conditions. This requires special approval and is given under strict regulations to patients who have serious or life-threatening conditions.

2. **Off-label Treatments**: Off-label use of medications for symptom management might be considered, such as:
- Behavioral therapy and educational support for intellectual disabilities.
- Hormonal treatments or growth hormone therapy for short stature.
- Nutritional and exercise regimens for weight management.

3. **Experimental Treatments**: Ongoing research might provide experimental treatments that could be relevant:
- Clinical trials targeting genetic or molecular pathways involved in Snyder-Robinson syndrome.
- New therapies being investigated for similar genetic disorders that could potentially be applied.

Always consult with specialized healthcare providers to explore the most appropriate treatment options based on individual cases.
Lifestyle Recommendations: Given that X-linked intellectual disability-short stature-overweight syndrome is a genetic condition, lifestyle recommendations may focus on managing symptoms and improving overall quality of life. These could include:

1. **Diet and Nutrition**:
- Maintain a balanced diet to manage overweight issues.
- Consult a nutritionist for individualized dietary plans.

2. **Physical Activity**:
- Engage in regular, suitable physical activities tailored to the individual's abilities to help manage weight and improve overall health.

3. **Medical Monitoring**:
- Regular follow-ups with healthcare providers to monitor growth, weight, and any other health concerns.

4. **Educational Support**:
- Access to special education resources or individualized education programs (IEPs) to support intellectual development.

5. **Therapies**:
- Occupational therapy to enhance daily living skills.
- Speech therapy if there are any speech and communication difficulties.

6. **Psychosocial Support**:
- Counseling or support groups for emotional and social well-being.
- Family support and education about the condition.

These lifestyle recommendations should always be tailored to individual needs and done in consultation with healthcare professionals.
Medication: There is no specific medication for X-linked intellectual disability-short stature-overweight syndrome. Treatment focuses on managing individual symptoms and may involve a multidisciplinary approach, including medical professionals such as geneticists, endocrinologists, dietitians, and physical therapists. Behavioral interventions, educational support, and therapies tailored to the individual's needs are also critical components of managing the condition.
Repurposable Drugs: There are no widely recognized and specific repurposable drugs for X-linked intellectual disability-short stature-overweight syndrome (XLSO). Treatment primarily focuses on managing symptoms and providing supportive care, such as educational support, physical therapy, and potentially medications to address specific behavioral or medical issues. Consultation with healthcare specialists is essential for tailoring interventions to individual needs.
Metabolites: There is limited specific information available regarding the metabolites directly associated with X-linked intellectual disability-short stature-overweight syndrome. This is a rare genetic condition and individual metabolic profiles can vary. Generally, genetic and metabolic evaluations by healthcare professionals are recommended to understand any underlying metabolic abnormalities or needs for personalized medical care in affected individuals.
Nutraceuticals: There are no specific nutraceuticals that have been proven to treat X-linked intellectual disability-short stature-overweight syndrome. Management of this condition typically focuses on addressing the individual symptoms through conventional medical care, dietary management, and supportive therapies. Nutraceuticals may be considered as part of a broader health strategy but should be discussed with a healthcare provider.
Peptides: Peptides and nanoparticles (nan) are not directly associated with the treatment or management of X-linked intellectual disability-short stature-overweight syndrome (also known as Snyder-Robinson Syndrome). This genetic condition is caused by mutations in the SMS gene, which affects the production of spermine synthase. Typical approaches to managing the symptoms of this syndrome include supportive care, developmental therapies, and addressing specific symptomatic issues. Research into advanced therapies, such as gene therapy, might provide future avenues for treatment, but as of now, peptides and nanoparticles are not standard in managing this condition.